Genmab

News
genmab-cph_349

Denmark's Genmab prepares for $500m US IPO

Antibody-based drugs firm Genmab, noted for developing the blood cancer drug Darzalex with Johnson & Johnson’s Janssen unit, is preparing for a $500 million US IPO.